Catalytic asymmetric conjugate addition of terminal alkynes to β -trifluoromethyl α , β -enones \dagger

Amparo Sanz-Marco,^a Andrea García-Ortiz,^a Gonzalo Blay*^a and José R. Pedro*^a

Departament de Química Orgànica, Facultat de Química, Universitat de València, C/ Dr. Moliner, 50, E-46100 Burjassot (València), Spain

SUPPORTING INFORMATION

Table of Contents:

General Experimental Methods	S2
Typical procedures and characterization data for compounds 3	S2
Determination of the absolute configuration of (S)-(-)-3aa	S11
Synthesis of compounds 6 and 7	S12
NMR spectra	S14
Chiral analysis chromatograms	S82

General Experimental Methods

Reactions were carried out under nitrogen in round bottom flasks oven-dried overnight at 120 °C. Commercial reagents were used as purchased. β -Trifluoromethyl- α , β -enones were prepared from the corresponding substituted acetophenones 1 and trifluoroacetaldehyde hemiacetal as described in the literature.¹ Toluene was distilled from CaH₂ Tetrahydrofuran (THF) was distilled from Na. Triethylamine was dried and stored on 4 Å molecular sieves. Reactions were monitored by TLC analysis using Merck Silica Gel 60 F-254 thin layer plates. Flash column chromatography was performed on Merck silica gel 60, 0.040-0.063 mm. Melting points were determined in capillary tubes. NMR spectra were run at 300 MHz for ¹H and at 75 MHz for ¹³C NMR using residual nondeuterated solvent (CHCl₃) as internal standard (δ 7.26 and 77.0 ppm, respectively), and at 282 MHz for ¹⁹F NMR using CFCl₃ as internal standard. Chemical shifts are given in ppm. The carbon type was determined by DEPT experiments. High resolution mass spectra (ESI) were recorded on a Q-TOF spectrometer equipped with an electrospray source with a capillary voltage of 3.3 kV (ESI). Specific optical rotations were measured using sodium light (D line 589 nm). Chiral HPLC analyses were performed in a chromatograph equipped with a UV diode-array detector using chiral stationary columns from Daicel.

Typical procedures and characterization data for compounds 3

General procedure for the enantioselective alkynylation reaction

[Cu(CH₃CN)₄]BF₄ (5.7 mg, 0.018 mmol) and L4 (12.4 mg, 0.018 mmol) were placed in a dry round bottom flask which was purged with nitrogen. THF (0.2 mL) was added and the mixture was stirred for 1.5 h at room temperature. Then, a solution of β trifluoromethyl- α , β -enone 2 (0.090 mmol) in dry THF (1.0 mL) was added via syringe, followed of triethylamine (12.5 μ L, 0.090 mmol). The solution was placed in a bath at 40 °C. After 10 min, the alkyne 1 (0.675mmol) was added and the solution was stirred at 40 °C under nitrogen until the reaction was complete (TLC). The reaction mixture was quenched with 20% aqueous NH₄Cl (1.0 mL), extracted with CH₂Cl₂ (2 × 15 mL), washed with brine (15 mL), dried over MgSO₄ and concentrated under reduced pressure. Purification by flash chromatography on silica gel eluting with hexane:diethyl ether mixtures afforded compound **3**.

(S)-(-)-3-(Trifluoromethyl)-1,5-diphenylpent-4-yn-1-one (3aa)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (85%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 8.1$ min, minor enantiomer $t_r = 10.1$ min.

 $[\alpha]_{D}^{20}$ –34.7 (*c* 0.81, CHCl₃, 85% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 8.03-7.99 (m, 2H), 7.62 (ddd, *J* = 6.6, 1.3 Hz, 2H), 7.40-7.37 (m, 2H), 7.31-7.24 (m, 3H), 4.29-4.16 (m,

1H), 3.60 (dd, J = 17.3, 8.9 Hz, 1H), 3.42 (dd, J = 17.3, 4.2 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 194.5 (C), 136.1 (C), 133.8 (CH), 131.9 (2CH), 128.8 (2CH), 128.6 (CH), 128.2 (2CH), 128.2 (2CH), 125.3 (q, $J_{C-F} = 263.0$ Hz, CF₃), 122.0 (C), 84.3 (C), 81.4 (q, $J_{C-F} = 6.5$ Hz, C), 38.3 (CH₂), 33.7 (q, $J_{C-F} = 41.2$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.6 (s, 3F); HRMS (ESI) *m*/*z*: 303.0893 (M + H)⁺, C₁₈H₁₄F₃O requires 303.0991.

(S)-(-)-3-(Trifluoromethyl)-5-phenyl-1-*p*-tolylpent-4-yn-1-one (3ab)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (80%) was determined by chiral HPLC (Chiralpak AD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r =$ 8.1 min, minor enantiomer $t_r =$ 9.1 min.

[α]_D²⁰ –28.5 (*c* 0.89, CHCl₃, 80% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.92-7.88 (m, 2H), 7.40-7.36 (m, 2H), 7.31-7.26 (m, 5H), 4.26-4.19 (m, 1H), 3.56 (dd, J = 17.2, 8.9 Hz, 1H), 3.39 (dd, J = 17.2, 4.2 Hz, 1H), 2.43 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃) δ 194.1 (C), 144.7 (C), 133.6 (C), 131.9 (2CH), 129.5 (2CH), 128.6 (CH), 128.2 (2CH), 127.2 (2CH), 125.4 (q, $J_{C-F} = 279.3$ Hz, CF₃), 122.0 (C), 84.7 (C), 84.2 (C), 38.1 (CH₂), 33.7 (q, $J_{C-F} = 31.7$ Hz, CH), 21.7 (CH₃); ¹⁹F NMR (282 MHz, CDCl₃) δ –71.6 (s, 3F); HRMS (ESI) *m/z*: 317.1148 (M+H)⁺, C₁₉H₁₆F₃O requires 317.1141.

(S)-(-)-3-(Trifluoromethyl)-1-(4-methoxyphenyl)-5-phenylpent-4-yn-1-one (3ac)



Purified by flash chromatography eluting with hexane-diethyl ether (99:01). Enantiomeric excess (80%) was determined by chiral HPLC (Chiralpak IC), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 9.0$ min, minor enantiomer $t_r = 8.0$

min.

[α]_D²⁰ –40.9 (*c* 0.91, CHCl₃, 80% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.88 (dt, J = 9, 3 Hz, 2H), 7.29-7.26 (m, 2H), 7.19-7.16 (m, 3H), 6.89-6.84 (dt, J = 9, 3 Hz, 2H), 4.16-4.09 (m, 1H), 3.70 (s, 3H), 3.43 (dd, J = 18, 9 Hz, 1H), 3.25 (dd, , J = 18, 3 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 193.0 (C), 164.0 (C), 131.9 (2CH), 130.6 (2CH), 129.2 (C), 128.6 (CH), 128.2 (2CH), 125.4 (q, $J_{C-F} = 279.4$ Hz, CF₃), 122.1 (C), 114.0 (2CH), 84.3 (C), 82.0 (q, $J_{C-F} = 3.8$ Hz, C), 55.5 (CH₃), 37.9 (CH₂), 33.8 (q, $J_{C-F} = 31.6$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ –71.6 (s, 3F); HRMS (ESI) *m/z*: 333.1088 (M + H)⁺, C₁₉H₁₆F₃O₂ requires 333.1097.

(S)-(-)-1-(4-Chlorophenyl)-3-(trifluoromethyl)-5-phenylpent-4-yn-1-one (3ad)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (80%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 7.5$ min, minor enantiomer $t_r = 10.9$ min.

[α]_D²⁰ –32.7 (*c* 0.81, CHCl₃, 80% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.95 (dt, J = 9.0, 3.0 Hz, 2H), 7.48 (dt, J = 9.0, 2.4 Hz, 2H), 7.40-7.36 (m, 2H), 7.31-7.24 (m, 3H), 4.27-4.14 (m, 1H), 3.55 (dd, J = 17.3, 8.9 Hz, 1H), 3.38 (dd, J = 17.3, 4.2 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 193.4 (C), 140.4 (C), 134.4 (C), 131.9 (2CH), 129.6 (2CH), 129.2 (2CH), 128.7 (CH), 128.2 (CH), 125.4 (q, $J_{C-F} = 279.3$ Hz, CF₃), 121.9 (C), 84.5 (C), 81.6 (q, $J_{C-F} = 3.9$ Hz, C), 38.3 (CH₂), 33.7 (q, $J_{C-F} = 31.5$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ –71.7 (s, 3F); HRMS (ESI) *m/z*: 337.0592/339.0564 (M + H)⁺ 100/32.0, C₁₈H₁₃F₃O₃Cl requires 337.0607/339.0578.

(S)- (-)-3-(Trifluoromethyl)-1-(4-nitrophenyl)-5-phenylpent-4-yn-1-one (3ae)



Purified by flash chromatography eluting with hexane-diethyl ether (95:05). Enantiomeric excess (70%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 95:05, 1 mL/min, major enantiomer $t_r = 20.1$ min, minor enantiomer $t_r = 31.2$

min.

[α]_D²⁰ –25.2 (*c* 0.60, CHCl₃, 70% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 8.35 (dt, J = 9.0, 3.0 Hz, 2H), 8.16 (dt, J = 9.0, 3.0 Hz, 2H), 7.40-7.25 (m, 5H), 4.27-4.15 (m, 1H), 3.63 (dd, J = 17.5, 8.9 Hz, 1H), 3.47 (dd, J = 17.5, 4.2 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 193.2 (C), 150.7 (C), 140.4 (C), 131.9 (2CH), 129.3 (2CH), 128.9 (CH), 128.3 (2CH), 125.1 (q, $J_{C-F} = 281.3$ Hz, CF₃), 124.1 (2CH), 121.7 (C), 84.8 (C), 81.1 (C), 38.9 (CH₂), 33.7 (q, $J_{C-F} = 31.9$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ –71.6 (s, 3F); HRMS (ESI) *m*/*z*: 348.0851 (M+H)⁺, C₁₈H₁₃F₃NO₃ requires 348.0848.

(S)-(-)-3-(Trifluoromethyl)-1-(naphthalene-3-yl)-5-phenylpent-4-yn-1-one (3af)



Purified by flash chromatography eluting with hexane-diethyl ether (99:01). Enantiomeric excess (84%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 16.3$ min, minor enantiomer $t_r = 19.1$

min.

 $[\alpha]_D^{20}$ –118.6 (*c* 1.30, CHCl₃, 84% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 8.50 (s, 1H), 8.05 (dd, *J* = 8.6, 1.8 Hz, 1H), 7.98 (d, *J* = 7.9 Hz, 1H), 7.90 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.65-7.54 (m, 2H), 7.38-7.35 (m, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, *J* = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 3.73 (dd, J = 10.2, 8.6 Hz, 2H), 7.28-7.20 (m, 3H), 4.35-4.22 (m, 1H), 7.28-7.20 (m, 2H), 7.28-7.20 (m,

17.2, 8.9 Hz, 1H), 3.54 (dd, J = 17.2, 4.1 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 194.4 (CH), 135.9 (C), 133.5 (C), 132.4 (C),131.8 (2CH), 130.12 (CH), 129.64 (CH), 128.9 (CH), 128.7 (CH), 128.6 (CH), 128.2 (2CH), 127.8 (CH), 127.0 (CH), 125.4 (q, $J_{C-F} = 279.4$ Hz, CF₃), 123.7 (CH), 122.0 (C), 84.4 (C), 81.9 (q, $J_{C-F} = 3.5$ Hz, C), 38.3 (CH₂), 33.8 (q, $J_{C-F} = 31.8$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.5 (s, 3F); HRMS (ESI) m/z: 353.1148 (M+H)⁺, C₂₂H₁₆F₃O requires 353.1148.

(S)-(-)-3-(Trifluoromethyl)-5-phenyl-1-(thiophen-2-yl)pent-4-yn-1-one (3ag)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (90%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 10.5$ min, minor enantiomer $t_r = 15.2$ min.

[α]_D²⁰ –6.1 (*c* 1.09, CHCl₃, 90% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.77 (dd, J = 3.8, 1.1 Hz, 1H), 7.68 (dd, J = 5, 1.1 Hz, 1H), 7.36-7.33 (m, 2H), 7.28-7.22 (m, 3H), 7.14 (dd, J = 5, 3.8 Hz, 1H), 4.23-4.10 (m, 1H), 3.47 (dd, J = 16.6, 8.9 Hz, 1H), 3.32 (dd, , J = 16.6, 4.5 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 187.4 (C), 143.2 (C), 134.7 (CH), 132.7 (CH), 131.9 (2CH), 128.7 (CH), 128.3 (CH), 128.2 (2CH), 125.2 (q, $J_{C-F} = 278.7$ Hz, CF₃), 121.9 (C), 84.7 (C), 81.5 (C), 38.7 (CH₂), 33.8 (q, $J_{C-F} = 31.7$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.7 (s, 3F); HRMS (ESI) *m*/*z*: 309.0550 (M + H)⁺, C₁₆H₁₂F₃OS requires 309.0555.

(S)-(-)-3-(Trifluoromethyl)-5-(4-methoxyphenyl)-1-phenylpent-4-yn-1-one (3ba)



Purified by flash chromatography eluting with hexane-diethyl ether (99:01). Enantiomeric excess (83%) was determined by chiral HPLC (Chiralpak AD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 15.9$ min, minor enantiomer $t_r = 14.4$

min.

[α]_D²⁰ –20.3 (*c* 0.93, CHCl₃, 83% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 8.02-7.99 (m, 2H), 7.64-7.59 (m, 1H), 7.53-7.47 (m, 2H), 7.31 (dt, *J* = 9, 3 Hz, 2H), 6.79 (dt, *J* = 9, 3 Hz, 2H), 4.27- 4.14 (m, 1H), 3.79 (s, 3H), 3.58 (dd, *J* = 17.2, 8.9 Hz, 1H), 3.41 (dd, *J* = 17.2, 4.2 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 194.7 (C), 159.8 (C), 136.1 (C), 133.7 (CH), 133.3 (2CH), 128.8 (2CH), 128.2 (2CH), 125.4 (q, *J*_{C-F} = 279.1 Hz, CF₃), 114.1 (C), 113.8 (2CH), 84.2 (C), 80.4 (q, *J*_{C-F} = 3.5 Hz, C), 55.3 (CH₃), 38.3 (CH₂), 33.7 (q, *J*_{C-F} = 31.7 Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ –71.7 (s, 3F); HRMS (ESI) *m/z*: 333.1088 (M + H)⁺ C₁₉H₁₆F₃O₂ requires 333.1097.

(S)-(-)-3-(Trifluoromethyl)-5-(4-fluorophenyl)-1-phenylpent-4-yn-1-one (3ca)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (80%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 8.8$ min, minor enantiomer $t_r = 10.8$ min.

[α]_D²⁰ –15.7 (*c* 1.15, CHCl₃, 80% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 8.02-7.99 (m, 2H), 7.65-7.60 (m, 1H), 7.53-7.48 (m, 2H), 7.39-7.34 (m, 2H), 7.00-6.93 (m, 2H), 4.24-4.17 (m, 1H), 3.59 (dd, *J* = 17.3, 9 Hz, 1H), 3.42 (dd, *J* = 17.3, 4.1 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 194.5 (C), 162.7 (d, *J* = 249.9 Hz, C), 136.0 (C), 133.9 (CH), 133.8 (d, *J* = 8.5 Hz, 2CH), 128.8 (2CH), 128.2 (2CH), 125.3 (q, *J* = 279.2 Hz, CF₃), 118.1 (d, *J* = 3.5 Hz, C), 115.5 (d, *J*_{C-F} = 22.1 Hz, 2CH), 83.3 (C), 81.6 (q, *J*_{C-F} = 5.1 Hz, C), 38.2 (CH₂), 33.6 (q, *J*_{C-F} = 31.6 Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ –71.6 (s, 3F), -110.7 (s, 1F); HRMS (ESI) *m/z*: 321.0892 (M+H)⁺, C₁₈H₁₃F₄O requires 321.0897.

(S)-(-)-5-(4-Chlorophenyl)-3-(trifluoromethyl)-1-phenylpent-4-yn-1-one (3da)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (77%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 10.5$ min, minor enantiomer $t_r = 11.5$ min.

[α]_D²⁰ –20.4 (*c* 0.90, CHCl₃, 77% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 8.02-7.99 (m, 2H), 7.62 (ddd, J = 6.6, 3.9, 1.3 Hz, 1H), 7.54-7.48 (m, 2H), 7.33-7.22 (m, 4H), 4.26-4.15 (m, 1H), 3.59 (dd, J = 17.3, 9 Hz, 1H), 3.42 (dd, J = 17.3, 4.1 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 194.4 (C), 136.0 (C), 134.7 (C), 133.8 (CH), 133.1 (2CH), 128.8 (2CH), 128.6 (2CH), 128.2 (2CH), 125.3 (q, $J_{C-F} = 279.4$ Hz, CF₃), 120.5 (C), 83.2 (C), 80.9 (C), 38.2 (CH₂), 33.7 (q, $J_{C-F} = 31.7$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ –71.5 (s, 3F); HRMS (ESI) *m/z*: 337.0594 / 339.0553 (M + H)⁺ 100 / 28.9 C₁₈H₁₃ClF₃O requires 337.0607 / 339.0578.

(S)-(-)-3-(Trifluoromethyl)-5-(4-methoxyphenyl)-1-(thiophen-2-yl)pent-4-yn-1-one (3bg)



Purified by flash chromatography eluting with hexane-diethyl ether (99:01). Enantiomeric excess (93%) was determined by chiral HPLC (Chiralpak AY-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 25.3$ min, minor enantiomer $t_r = 16.8$

min.

 $[\alpha]_{D}^{20}$ –7.3 (*c* 0.98, CHCl₃, 93% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.79 (dd, *J* = 3.8, 1.1 Hz, 1H), 7.72-7.70 (m, 1H), 7.32-7.28 (m, 2H), 7.17 (dd, *J* = 5, 3.8 Hz, 1H), 6.81-

6.77 (m, 2H), 4.23-4.11 (m, 1H), 3.79 (s, 3H), 3.48 (dd, J = 16.6, 8.9 Hz, 1H), 3.33 (dd, J = 16.6, 4.5 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 187.5 (C), 159.8 (C), 143.3 (C), 134.7 (CH), 133.3 (2CH), 132.6 (CH), 128.3 (CH), 125.2 (q, $J_{C-F} = 279.3$ Hz, CF₃), 114.0 (C), 113.8 (2CH), 84.6 (C), 80.0 (q, $J_{C-F} = 3.3$ Hz, C), 55.3 (CH₃), 38.8 (CH₂), 33.8 (q, $J_{C-F} = 31.7$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ –71.8 (s, 3F); HRMS (ESI) m/z: 338.0592 (M + H)⁺ C₁₇H₁₄F₃O₂S requires 338.0588.

(S)-(-)-3-(Trifluoromethyl)-5-(4-fluorophenyl)-1-(thiophen-2-yl)pent-4-yn-1-one (3cg)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (90%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 12.6$ min, minor enantiomer $t_r = 14.9$ min.

[α]_D²⁰ –6.4 (*c* 1.03, CHCl₃, 90% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.79 (dd, J = 3.9, 1.1 Hz, 1H), 7.72 (dd, J = 5, 1.1 Hz, 1H), 7.38-7-32 (m, 2H), 7.18 (dd, J = 5, 3.9 Hz, 1H), 7.00-6.93 (m, 2H), 4.23-4.08 (m, 1H), 3.49 (dd, J = 16.7, 9 Hz, 1H), 3.35 (dd, J = 16.7, 4.4 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 187.3 (C), 162.7 (d, J = 250 Hz, C), 143.2 (C), 134.8 (CH), 133.8 (d, J = 8.5 Hz, 2CH), 132.7 (CH), 128.3 (CH), 125.0 (q, $J_{C-F} = 279.5$ Hz, CF₃), 118.0 (C), 115.5 (d, J = 22.1 Hz, 2CH), 83.6 (C), 81.2 (q, $J_{C-F} = 3.6$ Hz, C), 38.7 (CH₂), 33.8 (q, $J_{C-F} = 31.9$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.6 (s, 3F), -110.7 (s, 1F); HRMS (ESI) *m*/*z*: 327.0455 (M + H)⁺ C₁₆H₁₁F₄OS requires 327.0461.

(S)-(-)- 5-(4-Chlorophenyl)-3-(trifluoromethyl)-1-(thiophen-2-yl)pent-4-yn-1-one (3dg)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (84%) was determined by chiral HPLC (Chiralpak IC), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 6.5$ min, minor enantiomer $t_r = 7.0$ min.

[α]_D²⁰ –6.9 (*c* 1.06, CHCl₃, 84% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.79 (dd, J = 3.9, 1.0 Hz, 1H), 7.22 (dd, J = 4.9, 1.0 Hz, 1H), 7.31-7.23 (m, 4H), 7.18 (dd, J = 4.9, 3.9 Hz, 1H), 4.21-4.14 (m, 1H), 3.49 (dd, J = 16.7, 9.0 Hz, 1H), 3.35 (dd, J = 16.7, 4.4 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 187.3 (C), 143.1 (C), 134.8 (C), 134.8 (CH), 133.1 (2CH), 132.6 (CH), 128.6 (2CH), 128.4 (CH), 125.1 (q, $J_{C-F} = 279.6$ Hz, CF₃), 120.4 (C), 83.6 (C), 82.5 (C), 38.6 (CH₂), 33.9 (q, $J_{C-F} = 31.9$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.5 (s, 3F); HRMS (ESI) *m*/*z*: 343.0158 / 345.0128 (M + H)⁺ 100 / 36.7 C₁₆H₁₁ClF₃OS requires 343.0171 / 345.0142.

(S)-(-)-3-(Trifluoromethyl)-5-(2-methoxyphenyl)-1-(thiophen-2-yl)pent-4-yn-1-one (3eg)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (98%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 95:05, 1 mL/min, major enantiomer $t_r = 10.7$ min, minor enantiomer $t_r = 13.2$ min.

[α]_D²⁰ –7.8 (*c* 0.90, CHCl₃, 98% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.80 (dd, J = 3.9, 1.1 Hz, 1H), 7.70 (dd, J = 5.0, 1.1 Hz, 1H), 7.34-7.24 (m, 2H), 7.17 (dd, J = 4.9, 3.8 Hz, 1H), 6.91-6.77 (m, 2H), 4.29-4.21 (m, 1H), 3.78 (s, 3H), 3.52 (dd, J = 16.6, 8.5 Hz, 1H), 3.36 (dd, J = 16.6, 4.8 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 187.5 (C), 160.4 (C), 143.4 (C), 134.5 (CH), 133.7 (CH), 132.6 (CH), 130.1 (CH), 128.3 (CH), 125.2 (q, $J_{C-F} = 279.5$ Hz, CF₃), 120.3 (CH), 111.3 (C), 110.8 (CH), 85.5 (C), 81.1 (C), 55.7 (CH₃), 38.9 (CH₂), 34.1 (q, $J_{C-F} = 31.8$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ –71.6 (s, 3F); HRMS (ESI) *m*/*z*: 338.0590 (M + H)⁺ C₁₇H₁₄F₃O₂S requires 338.0588.

(S)-(-)-3-(Trifluoromethyl)-5-(3-fluorophenyl)-1-(thiophen-2-yl)pent-4-yn-1-one (3fg)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (99%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 13.7$ min, minor enantiomer $t_r = 10.9$ min.

[α]_D²⁰ -8.3 (*c* 0.87, CHCl₃, 99% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.79 (dd, J = 2.7, 1.3 Hz, 1H), 7.74 (ddd, J = 9.7, 4.9, 1.1 Hz, 1H), 7.28-7.14 (m, 3H), 7.08-6.98 (m, 2H), 4.25-4.13 (m, 1H), 3.50 (dd, J = 16.7, 9.0 Hz, 1H), 3.36 (dd, J = 16.7, 4.4 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 187.2 (C), 162.2 (d, $J_{C-F} = 246.7$ Hz, C), 143.1 (C), 134.8 (CH), 132.7 (CH), 129.8 (d, $J_{C-F} = 8.6$ Hz, CH), 128.4 (CH), 127.8 (d, $J_{C-F} = 3.1$ Hz, CH), 125.1 (q, $J_{C-F} = 279.4$ Hz, CF₃), 123.7 (d, $J_{C-F} = 9.4$ Hz, C), 118.7 (d, $J_{C-F} = 23.0$ Hz, CH), 116.1 (d, J = 21.2 Hz, CH), 83.4 (q, $J_{C-F} = 3.4$ Hz, C), 82.5 (d, $J_{C-F} = 3.5$ Hz, C), 38.6 (CH₂), 33.8 (q, $J_{C-F} = 31.9$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.6 (s, 3F), -113.4 (s, 1F); HRMS (ESI) *m*/*z*: 327.0457 (M + H)⁺ C₁₆H₁₁F₄OS requires 327.0461.

(S)-(-)-3-(trifluoromethyl)-5-(3,5-dimethoxyphenyl)-1-(thiophen-2-yl)pent-4-yn-1one (3gg)



Purified by flash chromatography eluting with hexane-diethyl ether (95:05). Enantiomeric excess (86%) was determined by chiral HPLC (Chiralpak AD-H), hexane-^{*i*}PrOH 95:05, 1 mL/min, major

enantiomer $t_r = 11.2$ min, minor enantiomer $t_r = 12.5$ min.

[α]_D²⁰ -7.0 (*c* 0.93, CHCl₃, 86% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.80 (dd, J = 3.8, 1.1 Hz, 1H), 7.71 (dd, J = 4.9, 1.1 Hz, 1H), 7.17 (dd, J = 4.9, 3.8 Hz, 1H), 6.51 (d, J = 2.3 Hz, 2H), 6.42 (t, J = 2.3 Hz, 1H), 4.22-4.15 (m, 1H), 3.75 (s, 6H), 3.49 (dd, J = 16.6, 8.9 Hz, 1H), 3.35 (dd, J = 16.6, 4.5 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 187.4 (C), 160.4 (2C), 143.2 (C), 134.7 (CH), 132.7 (CH), 130.7 (CH), 125.2 (q, $J_{C-F} = 279.3$ Hz, CF₃), 123.2 (C), 109.6 (2CH), 102.3 (CH), 84.7 (C), 80.0 (q, $J_{C-F} = 3.4$ Hz, C), 55.4 (2CH₃), 38.7 (CH₂), 33.8 (q, _{C-F}J = 31.8 Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.6 (s, 3F); HRMS (ESI) m/z: 368.0690 (M + H)⁺ C₁₈H₁₅F₃O₃S requires 368.0694.

(S)-(-)-3-(Trifluoromethyl)-1-(thiophen-2-yl)-5-(thiophen-3-yl)pent-4-yn-1-one (3hg)



Purified by flash chromatography eluting with hexanediethyl ether (99:01). Enantiomeric excess (88%) was determined by chiral HPLC (Chiralcel OD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 11.1$ min, minor enantiomer $t_r = 15.5$ min.

[α]_D²⁰ –5.4 (*c* 0.86, CHCl₃, 88% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.79 (dd, J = 3.9, 1.1 Hz, 1H), 7.71 (dd, J = 4.9, 1.1 Hz, 1H), 7.40 (dd, J = 3.0, 1.2 Hz, 1H), 7.22 (dd, J = 5.0, 3.0 Hz, 1H), 7.17 (dd, J = 5.0, 3.9 Hz, 1H), 7.04 (dd, J = 5.0, 1.2 Hz, 1H), 4.22-4.11 (m, 1H), 3.49 (dd, J = 16.7, 8.9 Hz, 1H), 3.34 (dd, J = 16.7, 4.4 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 187.3 (C), 143.2 (C), 134.7 (CH), 132.6 (CH), 129.9 (CH), 129.7 (CH), 128.3 (CH), 125.3 (CH), 125.1 (q, $J_{C-F} = 279.5$ Hz, CF₃), 120.9 (C), 81.1 (q, $J_{C-F} = 3.5$ Hz, C), 79.9 (C), 38.7 (CH₂), 33.8 (q, $J_{C-F} = 31.7$ Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.6 (s, 3F); HRMS (ESI) *m*/*z*: 314.0043 (M + H)⁺ C₁₄H₉F₃OS₂ requires 314.0047.

(S)-(+)-7-phenyl-1-(thiophen-2-yl)-3-(trifluoromethyl)hept-4-yn-1-one (3ig)



Purification by flash chromatography eluting with hexane-diethyl ether (99:01). Enantiomeric excess (92%) was determined by chiral HPLC (Chiralcel AD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 9.7$ min, minor enantiomer $t_r = 10.8$ min.

[α]_D²⁰+1.2 (*c* 0.73, CHCl₃, 92% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.71 (td, J = 4.7, 1.2 Hz, 2H), 7.26-7.12 (m, 6H), 4.05 (m, 1H), 3.31 (dd, J = 16.6, 9.0 Hz, 1H), 3.19 (dd, J = 16.6, 4.5 Hz, 1H), 2.74 (t, J = 7.2 Hz, 2H), 2.42 (td, J = 7.5, 2.4 Hz, 2H); ¹³C NMR (75.5 MHz, CDCl₃) δ 187.6 (C), 143.4 (C), 140.3 (C), 134.5 (CH), 132.5 (CH), 128.5 (2CH), 128.3 (3CH), 126.2 (CH), 125.5 (q, $J_{C-F} = 277.5$ Hz, CF₃), 84.6 (C), 73.3 (C), 38.9 (CH₂), 34.6 (CH₂), 33.3 (q, $J_{C-F} = 30.8$ Hz, CH), 20.8 (CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ -72.1 (s, 3F); HRMS (ESI) *m/z*: 337.0854 (M + H)⁺ C₁₈H₁₆F₃OS requires 337.0868.

(S)-(+)-5-(Trifluoromethyl)-1,7-diphenylhept-6-yn-3-one (3ah)



Purification by flash chromatography eluting with hexane-diethyl ether (99:01). Enantiomeric excess (79%) was determined by chiral HPLC (Chiralcel AD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 6.6$ min, minor enantiomer $t_r = 9.6$

min.

[α]_D²⁰ +6.1 (*c* 0.8, CHCl₃, 79% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.42-7.36 (m, 2H), 7.35-7.22 (m, 5H), 7.24-7.14 (m, 2H), 3.99 (m, 1H), 3.01-2.78 (m, 6H); ¹³C NMR (75.5 MHz, CDCl₃) δ 204.3 (C), 140.4 (C), 131.9 (CH), 128.7 (CH), 128.6 (CH), 128.3 (CH), 126.3 (CH), 125.1 (q, $J_{C-F} = 277.1$ Hz, CF₃), 121.9 (C), 84.4 (C), 81.5 (q, $J_{C-F} = 3.6$ Hz, C), 44.7 (CH₂), 42.1 (CH₂), 33.4 (q, $J_{C-F} = 31.7$ Hz, CH), 29.5 (CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.8 (s, 3F); HRMS (ESI) *m/z*: 331.1306 (M + H)⁺ C₂₀H₁₈F₃O requires 331.1304.

(S)-(+)-5-(Trifluoromethyl)-7-(4-methoxyphenyl)-1-phenylhept-6-yn-3-one (3bh)



Purification by flash chromatography eluting with hexane-diethyl ether (99:01). Enantiomeric excess (82%) was determined by chiral HPLC (Chiralcel AD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 11.3$ min, minor

enantiomer $t_r = 17.4$ min.

[α]_D²⁰ +3.0 (*c* 0.5, CHCl₃, 82% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.33 (d, *J* = 9.0 Hz, 2H), 7.31-7.12 (m, 6H), 6.82 (d, *J* = 9.0 Hz, 2H), 3.98 (m, 1H), 3.81 (s, 3H), 3.00-2.78 (m, 6H); ¹³C NMR (75.5 MHz, CDCl₃) δ 204.4 (C), 159.9 (C), 140.5 (C), 140.5 (CH), 133.4 (CH), 128.6 (CH), 128.3 (CH), 126.3 (CH), 125.2 (q, *J*_{C-F} = 278.3 Hz, CF₃), 114.0 (C), 113.9 (CH), 84.3 (C), 80.1 (q, *J*_{C-F} = 1.6 Hz, C), 55.3 (CH₃), 44.8 (CH₂), 42.1 (CH₂), 33.4 (q, *J*_{C-F} = 31.5 Hz, CH), 29.5 (CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.9 (s, 3F); HRMS (ESI) *m/z*: 361.1415 (M + H)⁺ C₂₁H₂₀F₃O₂ requires 361.1410.

Determination of the absolute configuration of (S)-(-)-3aa



(E,S)-3-(Trifluoromethyl)-1,5-diphenylpent-4-en-1-ol (4)

Lithium aluminium hydride (12.1 mg, 0.320 mmol) was added to a solution of 3aa (16.1 mg, 0.053 mmol, 80% ee) in dry THF (1.5 mL) at room temperature, and the solution was stirred overnight

at 75 °C. The reaction mixture was quenched with 20 % aqueous NH₄Cl (1.0 mL), extracted with CH₂Cl₂ (2 x 15 mL), washed with brine (15 mL), dried over MgSO₄ and concentrated under reduced pressure. Purification by flash chromatography on silica gel eluting with hexane: EtOAc (98:02) afforded compound 4 (16.2 mg, 99%) as a mixture of diastereomers.

(E,S)-3-(Trifluoromethyl)-1,5-diphenylpent-4-en-1-one (5)^{2,3}

 $F_3 O$ To a 25 mL round-bottom flask equipped with a magnetic stirring bar was added PCC (137 mg, 0.64 mmol), 4Å MS (300 mg), silica gel (300 mg) and CH₂Cl₂ (10 mL). The mixture was cooled to 0 °C

and the mixture of alcohols 4 (16.2 mg, 0.05 mmol) in CH₂Cl₂ (1 mL) was added dropwise. The reaction was warmed up to room temperature and was stirred for 3 h. The mixture was filtered through a pad of silica gel eluting with CH₂Cl₂. The solvent was removed under reduced pressure. The residual crude product was purified by flash column chromatography eluting with hexane: Et_2O (99:01) to afford the ketone 5 (10.5 mg, 66%).

Enantiomeric excess (78%) was determined by chiral HPLC (Chiralpak AD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 9.6$ min, minor enantiomer $t_r = 10.8$ min. (lit^{2,3}, Chiralpak AD-H, hexane-^{*i*}PrOH 99.6:0.4, flow = 0.7 mL/min, *R*-enantiomer $t_r =$ 19.3 min, S-enantiomer $t_r = 16.3 \text{ min}$; $[\alpha]_D^{20} + 4.9$ (c 0.57, CCl₄, 78% ee) {lit^{2,3}[α]_D²⁰ -16.5 (0.95, CCl₄, 40% ee) for the *R*-isomer];¹H NMR (300 MHz, CDCl₃) δ 7.98-7.95 (m, 2H), 7.62-7.57 (m, 1H), 7.51-7.46 (m, 2H), 7.37-7.24 (m, 5H), 6.70 (d, J = 15.9 Hz, 1H), 6.04 (dd, J = 15.9, 8.6 Hz, 1H), 3.93-3.83 (m, 1H), 3.40-3.38 (m, 2H); ¹³C NMR (75.5 MHz, CDCl₃) δ 195.4 (C), 136.4 (C), 136.3 (CH), 136.1 (C), 133.6 (CH), 128.8 (2CH), 128.5 (2CH), 128.1 (CH), 128.1 (2CH), 126.9 (q, J = 274.7 Hz, CF₃), 121.5 (q, J = 2.4 Hz, CH), 42.6 (q, J = 27.7 Hz, CH), 37.4 (s, CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.2 (s, 3F); HRMS (ESI) m/z; 305.1158 (M + H)⁺ C₁₈H₁₆F₃O requires 305.1153.

Synthetic transformations of compound 3aa. Synthesis of compounds 6 and 7

(Z,S)-(-)-1,5-Diphenyl-3-(trifluoromethyl)pent-4-en-1-one (6)



A solution of (S)-**3aa** (10.6 mg, 0.035 mmol, 80% ee) in benzene (0.5 mL) was stirred in the presence of Lindlar's catalyst (2.5 mg) under hydrogen atmosphere (balloon) for 1 h. Then, the reaction mixture was filtered through a pad of Celite® eluting with EtOAc. The solvent was removed under reduced pressure to give **5** (9.4 mg, 88%).

Enantiomeric excess (80%) was determined by chiral HPLC (Chiralpak AD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer $t_r = 7.7$ min, minor enantiomer $t_r = 7.3$ min.

[α]_D²⁰ -70.2 (*c* 0.45, CHCl₃, 80% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.79 (dd, J = 3.9, 1.1 Hz, 1H), 7.71 (dd, J = 4.9, 1.1 Hz, 1H), 7.40 (dd, J = 3.0, 1.2 Hz, 1H), 7.22 (dd, J = 5.0, 3.0 Hz, 1H), 7.17 (dd, J = 5.0, 3.9 Hz, 1H), 7.04 (dd, J = 5.0, 1.2 Hz, 1H), 4.22-4.11 (m, 1H), 3.49 (dd, J = 16.7, 8.9 Hz, 1H), 3.34 (dd, J = 16.7, 4.4 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 195.5 (C), 136.3 (C), 135.9 (C), 135.7 (CH), 133.4 (CH), 128.7 (2CH), 128.4 (2CH), 128.3 (2CH), 128.1 (2CH), 127.5 (CH), 125.1 (q, J = 279.5 Hz, CF₃), 123.8 (q, J = 2.3 Hz, CH), 38.3 (q, J = 27.4 Hz, CH), 38.0 (q, J = 1.8 Hz, CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ -71.0 (s, 3F); HRMS (ESI) *m/z*: 305.1159 (M + H)⁺ C₁₈H₁₆F₃O requires 305.1153.

(R)-(-)-3-Iodo-2,6-diphenyl-4-(trifluoromethyl)-4H-pyran (7).

Ph O Ph A solution of I₂ (30.1 mg, 0.119 mmol) in CH₂Cl₂ (2 mL) was added to a mixture of (*S*)-**3aa** (18 mg, 0.060 mmol 85% *ee*) and NaHCO₃ (10 mg, 0.119 mmol) under nitrogen atmosphere. The solution was stirred overnight at 40 °C (reflux). The reaction mixture was quenched with saturated aqueous Na₂S₂O₃ (1.0 mL), extracted with CH₂Cl₂ (2 × 15 mL), washed with brine (15 mL), dried over MgSO₄ and concentrated under reduced pressure. Purification by flash chromatography on silica gel eluting with hexane:Et₂O (98:02) gave compound 7 (19.9 mg, 77%). Enantiomeric excess (84%) was determined by chiral HPLC (Chiralpak AD-H), hexane-^{*i*}PrOH 99:01, 1 mL/min, major enantiomer t_r = 6.5 min, minor enantiomer t_r = 4.7 min.

[α]_D²⁰ –7.0 (*c* 0.45, CHCl₃, 84% *ee*); ¹H NMR (300 MHz, CDCl₃) δ 7.69-7.58 (m, 4H), 7.54-7.42 (m, 3H), 7.42-7.34 (m, 3H), 5.29 (d, J = 5.8 Hz, 1H), 4.16-4.02 (m, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 155.1 (C), 153.1 (C), 135.9 (C), 132.3 (C), 129.9 (CH), 129.7 (2CH), 129.6 (CH), 128.7 (C), 128.5 (2CH), 128.2 (2CH), 125.4 (q, J = 223.7 Hz, CF₃), 125.0 (2CH), 90.4 (q, J = 1.8 Hz, CH), 49.5 (q, J = 22.7 Hz, CH); ¹⁹F NMR (282 MHz, CDCl₃) δ –74.4 (s, 3F); HRMS (ESI) *m*/*z*: 428.9961 (M + H)⁺ C₁₈H₁₃F₃IO requires 428.9958.

- 1. G. Blay, I. Fernández, M. C. Muñoz, J. R. Pedro, C. Vila *Chem. Eur. J.*, **2010**, *16*, 9117-9122.
- (a) A. Morigaki, T. Tanaka, T. Miyabe, T. Ishihara, T. Konno, *Org. Biomol. Chem.*, 2013, **11**, 586; (b) T. Konno, T. Tanaka, A. Morigaki, T. Ishihara, *Tetrahedron Lett.*, 2008, **49**, 2106
- 3. We thank Professor Tsutomu Konno, Kyoto Institute of Technology, for sending us complete characterization data of compound (*E*,*R*)-**5**.









S17



— -71.6



3ab ¹⁹F NMR, 282 MHz, CDCl₃









— -71.6











S26

4.25 4.23 4.20 4.19 4.18 3.673.673.613.613.613.613.503.533.533.533.533.533.533.533.533.533.543.543.543.543.543.543.543.543.553.543.553.543.553.543.553.543.553.543.553.543.553.543.553.543.553.543.543.553.54

— 193.2 131.9 130.7 129.3 129.3 128.9 128.9 128.9 128.9 128.3 127.0 127.0 127.0 127.1 — 140.4 84.8 81.2 81.2 81.1 81.1 81.1 77.4 77.4 77.0 76.6 CF₃ O NO₂ 3ae ¹³C NMR, 75.5 MHz, CDCl₃ -200 120 110 f1 (ppm) 80 70 40 160 140 130 190 180 170 150 100 90 60 50

Electronic Supplementary Material (ESI) for Chemical Communications This journal is C The Royal Society of Chemistry 2014







S28



S29







ÇF₃ O

3ag ¹H NMR, 300 MHz, CDCl₃



S32



S33





S35




— -71.7











— -71.5











































— -71.6







S64

— -71.6



- 1







131.9 128.7 128.6 128.6 128.3 128.3 128.3 128.3 128.3 128.3 128.3 128.3 128.3 128.3 140.4 × 84.4 × 81.5 77.4 77.0 76.6 34.0 33.6 33.2 32.7 29.5 44.7 42.1 CF₃ O 3ah ¹³C NMR, 75 MHz, CDCl₃ ไปสุดที่เป็นข่างแหนงแนนแหน่งไม่และและเป็นการสูงและการสูงและและเป็นสูงและเป็นหลายให้และและ f1 (ppm)








S73























No.	RT	Area	Area %
1 2	8,33 10,43	3924955 3835001	50,580 49,420
		7759956	100,000



No.	RT	Area	Area %	Name
1 2	8,08 10,07	11908140 966915	92,490 7,510	
		12875055	100,000	



No.	RT	Area	Area %	Name
1 2	7,59 8,49	11951084 11872001	50,166 49,834	
		23823085	100,000	



No.	RT	Area	Area %	Name
1 2	8,12 9,10	3979075 471170	89,412 10,588	
		4450245	100,000	



No.	RT	Area	Area %	Name
1 2	8,09 9,15	17412022 19383041	47,322 52,678	
		36795063	100,000	



No.	RI	Area	Area %	Nane
1 2	7,96 8,96	481630 4313950	10,043 89,957	
		4795580	100,000	



No.	RT	Area	Area %	Name
1 2	7,49 10,77	17075254 17075995	49,999 50,001	
		34151249	100,000	



No.	RT	Area	Area %	Name
1 2	7,53 10,94	12398415 1407990	89,802 10,198	
		13806405	100,000	



No.	RT	Area	Area %	Name
1 2	19,42 29,23	37529094 18616300	66,843 33,157	
		56145394	100,000	



No.	RT	Area	Area %	Name
1 2	20,09 31,23	25599854 4563240	84,871 15,129	
		30163094	100,000	





No.	RT	Area	Area %	Name
1 2	16,27 19,31	29305795 2560000	91,966 8,034	
		31865795	100,000	



No.	RT	Area	Area %	Name
1 2	10,24 15,09	8252040 7921200	51,023 48,977	
		16173240	100,000	



No.	RT	Area	Area %	Name
1 2	10,47 15,19	11482160 620500	94,873 5,127	
		12102660	100,000	



No.	RT	Area	Area %	Name
1 2	13,31 14,87	2676360 2684990	49,920 50,080	
		5361350	100,000	



No.	RT	Area	Area %	Name
1 2	14,37 15,88	828280 9001520	8,426 91,574	
		9829800	100,000	



No.	RT	Area	Area %	Name
1 2	8,63 10,62	9960184 10396870	48,927 51,073	
		20357054	100,000	



No.	RT	Area	Area %	Name
1 2	8,75 10,75	7870600 896555	89,774 10,226	
		8767155	100,000	







No.	RT	Area	Area %	Name
1 2	10,45 11,49	6311811 844093	88,204 11,796	
		7155904	100,000	



No.	RT	Area	Area %	Name
1 2	22,05 25,65	8539349 8638890	49,710 50,290	
		17178239	100,000	



No.	RT	Area	Area %	Name
1 2	16,83 25,25	1004280 26295569	3,679 96,321	
		27299849	100,000	



No.	RT	Area	Area %	Name
1 2	12,57 14,61	10194740 9938569	50,636 49,364	
		20133309	100,000	



No.	RT	Area	Area %	Name
1 2	12,54 14,87	9551030 527170	94,769 5,231	
		10078200	100,000	



No.	RT	Area	Area %	Name
1 2	6,42 6,90	3692928 3758161	49,562 50,438	
		7451089	100,000	



No.	RT	Area	Area %	Name
1 2	6,49 7,02	8573328 769626	91,762 8,238	
		9342954	100,000	



No.	RT	Area	Area %	Name
1 2	10,22 12,65	2889530 2910330	49,821 50,179	
		5799860	100,000	



No.	RT	Area	Area %	Name
1 2	10,69 13,20	21493235 276845	98,728 1,272	
		21770080	100,000	



No.	RT	Area	Area %	Name
1 2	11,04 15,39	16499859 16011619	50,751 49,249	
		32511478	100,000	



No.	RT	Area	Area %	Name
1 2	10,94 13,70	75945 17638089	0,429 99,571	
		17714034	100,000	



No.	RT	Area	Area %	Name
1	11,18	5055040	48,820	
2	12,37	5299460	51,180	
		10354500	100,000	



No.	RT	Area	Area %	Name
1 2	11,24 12,46	12062089 935910	92,800 7,200	
		12997999	100,000	



No.	RT	Area	Area %	Name
1 2	13,75 18,77	3495870 3325550	51,248 48,752	
		6821420	100,000	



No.	RT	Area	Area %	Name
1 2	11,09 15,52	10169350 656800	93,933 6,067	
		10826150	100,000	



No.	RT	Area	Area %	
1 2	9,41 10,46	3829870 3770840	50,388 49,612	
		7600710	100,000	



No.	RT	Area	Area %	
1 2	9,67 10,77	4974620 218520	95,792 4,208	
		5193140	100,000	



No.	RT	Area	Area %	Name
1 2	6,59 8,67	2026100 4449964	31,286 68,714	
		6476064	100,000	



No.	RT	Area	Area %	Name
1 2	6,63 9,63	1625410 194860	89,295 10,705	
		1820270	100,000	



No.	RT	Area	Area %	Name
1 2	13,57 20,79	8411390 8693320	49,176 50,824	
		17104710	100,000	



No.	RI	Area	Area %	Name
1 2	11,30 17,43	2495555 247250	90,986 9,014	
		2742805	100,000	



No.	RT	Area	Area %	Name
1 2	9,27 10,33	3064390 3123390	49,523 50,477	
		6187780	100,000	



No.	RT	Area	Area %	Name
1 2	9,64 10,75	11183110 1407330	88,822 11,178	
		12590440	100,000	



No.	RT	Area	Area %	Name
1 2	7,65 8,35	5623247 5667342	49,805 50,195	
		11290589	100,000	



No.	RT	Area	Area %	Name
1 2	7,25 7,73	648834 5797605	10,065 89,935	
		6446439	100,000	

